Cette nomination renforce la présence de TGV aux États-Unis et lui permet de se concentrer sur la région de la baie de San Francisco

SAN FRANCISCO et SINGAPOUR, 29 mai 2026 — True Global Ventures (TGV), société mondiale de capital-risque investissant dans des fondateurs visionnaires qui créent des entreprises technologiques de premier plan dans le domaine de l’IA, annonce aujourd’hui la nomination de Tal Elyashiv en tant que general partner.

Entrepreneur chevronné, investisseur en capital-risque et cadre dans le secteur des technologies, Elyashiv a mené une brillante carrière dans la Silicon Valley, à Wall Street et à Tel Aviv. Il apporte à l’entreprise une combinaison rare d’expertise en investissement dans les technologies de pointe, d’expérience en tant qu’opérateur et de leadership dans le domaine de la finance institutionnelle. Il s’installera aux États-Unis dans le courant de l’année, renforçant ainsi la présence croissante de TGV dans la région de la baie de San Francisco.

Israélien d’origine américaine ayant des racines dans deux des principaux écosystèmes d’innovation du monde, Elyashiv a passé des décennies à l’intersection de la technologie, des services financiers et du capital-risque.

Elyashiv est cofondateur et managing partner de SPiCE VC, le premier fonds de capital-risque entièrement tokenisé au monde. SPiCE VC est également reconnu comme un fonds de capital-risque très performant, avec de solides distributions par rapport au capital versé et une valeur totale par rapport au capital versé, surpassant de manière significative les indices de référence du secteur. Elyashiv poursuivra ses fonctions de direction au sein de SPiCE VC (actuellement dans sa phase finale de conversion de ses investissements) parallèlement à sa contribution à TGV.  Les mandats des fonds sont substantiellement différents et les deux fonctions ne présentent pas de conflit d’intérêt.

Outre son rôle de pionnier au sein de SPiCE VC, Elyashiv est également cofondateur de Securitize, qui est aujourd’hui la principale plateforme de tokenisation des actifs du monde réel à l’échelle mondiale et une entreprise déterminante dans le domaine des titres numériques. Il est également l’auteur de deux livres à succès, Blockchain Prophecies et l’ouvrage récemment publié Investing in Revolutions: Creating Wealth from Transformational Technology Waves, faisant de lui l’un des principaux leaders d’opinion sur la convergence de l’IA, de la blockchain et de l’informatique quantique.

Dans le domaine de la finance institutionnelle, il a été cadre supérieur chez Capital One et Bank of America, directeur de l’exploitation chez BondDesk Group, où il a dirigé le redressement majeur de la technologie et de la prestation de services, et directeur technique et responsable des nouvelles activités chez 888.

La nomination d’Elyashiv intervient alors que TGV continue d’accélérer sa focalisation sur les applications commerciales fondées sur l’IA par le biais du TGV Fund 6, qui dirige les investissements aux stades de l’amorçage tardif et de la série A, en mettant l’accent sur les startups basées en Californie.

« Tal apporte l’expérience de la gestion de fonds d’une société de capital-risque performante que nous recherchons chez TGV – en plus de cela, une personne qui a créé des entreprises, dirigé des institutions et investi avec conviction à travers de multiples cycles technologiques. Ses racines américaines et israéliennes lui confèrent une vision véritablement mondiale, et son retour aux États-Unis s’inscrit parfaitement dans le cadre de l’accent mis par TGV sur la région de la baie de San Francisco. Nous sommes ravis de l’accueillir dans notre équipe »
– Dušan Stojanović, managing partner, True Global Ventures

« TGV a construit quelque chose de rare – un fonds véritablement mondial avec le réseau, le portefeuille et la conviction de soutenir des fondateurs qui définissent des catégories aux stades les plus critiques de leur croissance. Après des décennies de construction à la frontière de la fintech et de la blockchain, je suis ravi de rejoindre une équipe qui partage ma conviction que l’IA et la blockchain sont les thèmes d’investissement déterminants de notre époque. Je me réjouis à la perspective de mettre mon expérience au service de True Global Ventures et de sa prochaine phase de croissance »
– Tal Elyashiv, general partner, True Global Ventures, managing partner, SPiCE VC

« La combinaison de Tal en tant qu’investisseur en capital-risque chevronné, opérateur prospère, dirigeant d’entreprise et expérience en matière de redressement est exceptionnelle. Il n’a pas seulement investi dans les domaines d’avant-garde, il les a construits. La profondeur et l’étendue de l’expertise de Tal et son exécution pratique seront un atout pour TGV et les entreprises de notre portefeuille au fur et à mesure qu’elles se développent. »
– Beatrice Lion, general partner, True Global Ventures

À PROPOS DE TRUE GLOBAL VENTURES
True Global Ventures (TGV) est une société mondiale de capital-risque qui investit dans des entreprises d’IA en phase de démarrage. Le portefeuille actuel de TGV comprend Prezent, Cynch, COVU, Obligo, Ledger, Animoca Brands, Jus Mundi, Coding Giants et bien d’autres. Presque toutes les sociétés de portefeuille se trouvent aux États-Unis ou entrent sur ce marché. Avec une présence à San Francisco, New York, Paris, Londres, Stockholm, Dubaï, Singapour et Hong Kong, TGV soutient les fondateurs visionnaires qui construisent la prochaine génération d’entreprises technologiques transformatrices. www.trueglobalventures.com

Photo – https://mma.prnewswire.com/media/2989447/1.jpg

Ernennung stärkt die US-Präsenz mit vertieftem Fokus von TGV auf die Bay Area

SAN FRANCISCO und SINGAPUR, 29. Mai 2026 — True Global Ventures (TGV), ein globales Risikokapitalunternehmen, das in visionäre Gründer investiert, die kategoriedefinierende KI-First-Technologieunternehmen aufbauen, gab heute die Ernennung von Tal Elyashiv zum General Partner bekannt.

Als erfahrener Unternehmer, Risikokapitalgeber und Führungskraft im Technologiebereich mit einer herausragenden Karriere im Silicon Valley, an der Wall Street und in Tel Aviv bringt Elyashiv eine seltene Kombination aus fundiertem Fachwissen im Bereich der Technologieinvestitionen, Erfahrung als Unternehmer und Führungsqualitäten im institutionellen Finanzwesen in das Unternehmen ein. Er wird noch in diesem Jahr in die USA umziehen und damit die wachsende Präsenz des TGV in der San Francisco Bay Area weiter verstärken.

Als amerikanischer Israeli mit Wurzeln in zwei der wichtigsten Innovationsökosysteme der Welt hat Elyashiv Jahrzehnte an der Schnittstelle von Technologie, Finanzdienstleistungen und Risikokapital verbracht.

Elyashiv ist Mitbegründer und Managing Partner von SPiCE VC, dem weltweit ersten vollständig tokenisierten Risikokapitalfonds. SPiCE VC ist auch als ein VC-Fonds mit Spitzenleistungen anerkannt, mit starken Ausschüttungen im Verhältnis zum eingezahlten Kapital (DPI) und dem Gesamtwert im Verhältnis zum eingezahlten Kapital (TVPI), die die Benchmarks der Branche deutlich übertreffen. Elyashiv wird seine Führungsrolle bei SPiCE VC (das sich derzeit in der Spätphase befindet) parallel zu seinem Beitrag bei TGV fortsetzen.  Die Mandate der Fonds sind sehr unterschiedlich und es besteht kein Interessenkonflikt zwischen den beiden Funktionen.

Neben seiner bahnbrechenden Führungsrolle bei SPiCE VC ist Elyashiv auch Mitbegründer von Securitize, der heute weltweit führenden Plattform für die Tokenisierung von realen Vermögenswerten und ein wegweisendes Unternehmen im Bereich der digitalen Wertpapiere. Er ist auch der Autor von zwei Bestsellern, Blockchain Prophecies und dem kürzlich veröffentlichten Investing in Revolutions: Creating Wealth from Transformational Technology Waves, wodurch er sich als einer der führenden Vordenker im Bereich der Konvergenz von KI, Blockchain und Quantencomputing etabliert hat.

Zu seinen früheren Funktionen im institutionellen Finanzwesen gehören die leitende Position bei Capital One und der Bank of America, die Position des Betriebsleiters bei der BondDesk Group, wo er den großen Turnaround der Technologie- und Servicebereitstellung leitete, sowie die Position des Technischen Leiters und Leiter für neue Geschäfte bei 888.

Die Ernennung von Elyashiv erfolgt zu einem Zeitpunkt, an dem TGV seinen Fokus auf KI-basierte Geschäftsanwendungen durch den TGV Fund 6 weiter verstärkt, der Investitionen in der späten Seed- und Series-A-Phase mit einem starken Fokus auf kalifornische Startups tätigt.

„Tal bringt die Erfahrung im Fondsmanagement eines erfolgreichen VCs mit, die wir bei TGV suchen – und darüber hinaus hat er über mehrere Technologiezyklen hinweg Unternehmen aufgebaut, Institutionen geleitet und mit Überzeugung investiert. Seine amerikanischen und israelischen Wurzeln verleihen ihm einen wahrhaft globalen Blickwinkel, und seine Rückkehr in die USA passt perfekt zum verstärktem Fokus von TGV auf die Bay Area. Wir freuen uns sehr, ihn in unserer Partnerschaft begrüßen zu dürfen.”
– Dušan Stojanović, Managing Partner, True Global Ventures

„TGV hat etwas Seltenes aufgebaut – einen wirklich globalen Fonds mit dem Netzwerk, dem Portfolio und der Überzeugung, kategorieprägende Gründer in den kritischsten Phasen ihres Wachstums zu unterstützen. Nachdem ich jahrzehntelang an der Grenze von Fintech und Blockchain gearbeitet habe, freue ich mich, einem Team beizutreten, das meine Überzeugung teilt, dass KI und Blockchain die entscheidenden Anlagethemen unserer Zeit sind. Ich freue mich darauf, meine Erfahrung in die Unterstützung von True Global Ventures und dessen nächstes Kapitel einzubringen.”
– Tal Elyashiv, General Partner, True Global Ventures, Managing Partner, SPiCE VC

„Tal bringt eine außergewöhnliche Kombination aus erfahrenem Risikokapitalgeber, erfolgreichem Betreiber, Unternehmensführung und Turnaround-Erfahrung. Er hat nicht nur an der Grenze investiert – er hat dort gebaut. Das umfassende und breit gefächerte Fachwissen von Tal und seine praktische Erfahrung werden für TGV und unsere Portfoliounternehmen bei ihrer Expansion von großem Nutzen sein.”
 – Beatrice Lion, General Partner, True Global Ventures

INFORMATIONEN ZU TRUE GLOBAL VENTURES
True Global Ventures (TGV) ist ein globales Risikokapitalunternehmen, das in der Frühphase in Unternehmen investiert, die auf KI spezialisiert sind. Zum aktuellen Portfolio von TGV gehören Prezent, Cynch, COVU, Obligo, Ledger, Animoca Brands, Jus Mundi, Coding Giants und viele andere. Fast alle Portfoliounternehmen befinden sich in den USA oder gehen in die USA. Mit Niederlassungen in San Francisco, New York, Paris, London, Stockholm, Dubai, Singapur und Hongkong unterstützt TGV visionäre Gründer, die die nächste Generation von transformativen Technologieunternehmen aufbauen. www.trueglobalventures.com

Foto – https://mma.prnewswire.com/media/2989447/1.jpg

The European approval lands alongside SHINE’s expansion into diagnostic radiopharmaceuticals. In January, the company acquired an established U.S. isotope manufacturing and distribution facility and product portfolio, adding decades of operational scale across diagnostic isotopes — Tc-99m generators, cardiac and neuroimaging agents, and Xe-133 for pulmonary imaging — used in millions of procedures each year. The combination gives hospitals, imaging centers, and radiopharmaceutical developers a single U.S.-based supplier across a wide spectrum of nuclear medicine.¹

“For years, our customers have asked for a reliable partner that can deliver both the diagnostic and therapeutic side of nuclear medicine,” said Michael Rossi, CEO of SHINE SPECT LLC. “EMA approval opens the door for SHINE’s radioisotope Lu-177 to be used in developing radioligand therapies at scale, and ultimately support the expanded reach of nuclear medicine to patients. Combined with the isotope manufacturing and distribution operation we run for North American hospitals and imaging centers, SHINE now serves both sides of nuclear medicine.”

A U.S. Production Platform Built for Reliability and Scale

SHINE produces Ilumira at its Cassiopeia facility in Janesville, Wisconsin, one of North America’s largest n.c.a. Lu-177 production sites, using a proprietary process. The facility provides commercial-scale supply for the global radiopharmaceutical market, with the ability to adjust capacity according to demand for approved Lu-177 therapies.

Ilumira is produced under cGMP and meets European Pharmacopeia standards. As a non-carrier-added product, Ilumira achieves ≥99.9% radionuclidic purity and high specific activity, characteristics that distinguish n.c.a. Lu-177 from carrier-added alternatives.^2,3 SHINE is one of the few lutetium producers that also recycles ytterbium (Yb-176), the starter material for all n.c.a. Lu-177. The result is less waste, improved efficiency, and a domestic supply chain radiopharmaceutical developers can plan around.

A New Era for Nuclear Medicine

The EMA approval is the latest in a series of major moves expanding SHINE’s nuclear medicine platform:

• SHINE acquired an established U.S. isotope manufacturing and distribution operation in January, expanding into diagnostic radiopharmaceuticals and adding immediate operational scale to its nuclear medicine platform
• The company closed a $240 million Series E led by Dr. Patrick Soon-Shiong in February. The investment included a strategic partnership with NantWorks featuring priority access to SHINE’s Lu-177 supply, positioning both companies to advance the next generation of targeted cancer treatment.
• SHINE received a $263 million conditional loan commitment from the U.S. Department of Energy in April to complete Chrysalis, designed to become the largest medical isotope production site in the world. The fusion-fission hybrid facility will produce molybdenum-99 — the parent isotope of the Tc-99m used in SHINE’s SPECT products — connecting the company’s isotope production to its diagnostic manufacturing under one supply chain.
• SHINE has also expanded its global distribution partnerships and built out its senior leadership team to support its next stage of growth.

With its integrated platform now spanning diagnostic and therapeutic radioisotopes from U.S. production, SHINE continues to scale capacity and expand global reach.

About Ilumira

Lu-177 is one of the most widely used isotopes in targeted cancer therapy. Paired with a targeting ligand, it delivers potent radiation to tumor cells while sparing healthy tissue.  Lu-177 is currently used as the nuclear isotope precursor in several radiopharmaceuticals that have approved and investigational uses across prostate cancer and neuroendocrine tumors, and a growing list of indications.²

Global demand for Lu-177 is soaring, but supply has been unstable, and most Lu-177 produced today is carrier-added, with lower radionuclidic purity.^2,3 Carrier-added Lu-177 contains non-therapeutic lutetium isotopes alongside the active material. Non-carrier-added Lu-177 separates them out for higher radionuclidic purity and a more concentrated source of active material.^2,3

Note: Ilumira is a radiopharmaceutical precursor, not a finished drug. It is solely intended for radiolabeling of carrier molecules and is not for direct patient use.

References:

[1] World Nuclear Association. Radioisotopes in medicine. Updated January 21, 2026. Accessed April 10, 2026. https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine

[2] Niu T, Fan M, Lin B, et al. Current clinical application of lutetium-177 in solid tumors (Review). Exp Ther Med. 2024;27(5):225. doi:10.3892/etm.2024.12514. PMID: 38596660; PMCID: PMC11002837. Accessed April 30, 2026.  https://pmc.ncbi.nlm.nih.gov/articles/PMC11002837/

[3] Dash A, Pillai MRA, Knapp FF Jr. Production of ^177Lu for Targeted Radionuclide Therapy: Available Options. Nucl Med Mol Imaging. 2015;49(2):85–107. Available from: PubMed Central. Accessed April 10, 2026

About SHINE

Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility.

SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy.

Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors.

Learn more at www.shinefusion.com.

SOURCE SHINE Technologies, LLC

De benoeming versterkt de aanwezigheid van de VS met de verdiepende focus van TGV in de Bay Area

SAN FRANCISCO en SINGAPORE, 29 mei 2026 — True Global Ventures (TGV), een wereldwijd durfkapitaalbedrijf dat investeert in visionaire oprichters die categorie-definiërende AI-first technologiebedrijven bouwen, kondigde vandaag de benoeming aan van Tal Elyashiv als Algemeen Partner.

Elyashiv, een ervaren ondernemer, venture capitalist en technologie-executive met een vooraanstaande carrière in Silicon Valley, Wall Street en Tel Aviv, brengt een zeldzame combinatie van deeptech-investeringsexpertise, ervaring als ondernemer en institutionele financieel leiderschap naar het bedrijf. Hij zal later dit jaar naar de VS verhuizen, waardoor de groeiende aanwezigheid van TGV in het San Francisco Bay Area verder wordt versterkt.

Elyashiv, een Amerikaans-Israëlische ondernemer met wortels in twee van ‘s werelds belangrijkste innovatie-ecosystemen, is al tientallen jaren actief op het snijvlak van technologie, financiële diensten en durfkapitaal.

Elyashiv is medeoprichter en managing partner van SPiCE VC, het eerste volledig getokeniseerde durfkapitaalfonds wereldwijd. SPiCE VC wordt ook erkend als een best presterend VC-fonds, met sterke distributies versus betaald kapitaal (DPI) en totale waarde versus betaald kapitaal (TVPI), die aanzienlijk beter presteren dan de benchmarks in de industrie. Elyashiv zal zijn leiderschap bij SPiCE VC (momenteel in de late oogstfase) parallel aan zijn bijdrage bij TGV voortzetten. De mandaten van de fondsen verschillen aanzienlijk en er bestaat geen belangenconflict tussen de twee rollen.

Naast zijn baanbrekende leiderschap bij SPiCE VC is Elyashiv ook medeoprichter van Securitize, nu het toonaangevende platform voor de tokenisatie van reële activa wereldwijd en een bepalend bedrijf in de digitale effectenruimte. Hij is ook de auteur van twee bestsellers, Blockchain Prophecies en het onlangs gepubliceerde Investing in Revolutions: Creating Wealth from Transformational Technology Waves, waardoor hij zich vestigt als een van de belangrijkste denkers op het gebied van de convergentie van AI, blockchain en kwantumcomputing.

Zijn eerdere rollen in institutionele financiering omvatten het dienen als senior executive bij Capital One en Bank of America, COO bij BondDesk Group, waar hij de grote ommekeer van technologie en dienstverlening leidde, en als CTO en hoofd van New Businesses bij 888.

De benoeming van Elyashiv komt omdat TGV zijn focus op AI-first zakelijke toepassingen blijft versnellen via TGV Fund 6, dat investeringen leidt in de late seed- en Series A-stadia met een sterke nadruk op in Californië gevestigde startups.

“Tal brengt de fund management-ervaring van een goed presterende VC die we bij TGV zoeken, bovenop iemand die bedrijven heeft opgebouwd, instellingen heeft geleid en met overtuiging heeft geïnvesteerd in meerdere technologische cycli. Zijn Amerikaanse en Israëlische wortels geven hem een echt wereldwijde zienswijze en zijn terugkeer naar de VS sluit perfect aan bij de verdiepende focus van TGV op de Bay Area. Wij zijn verheugd hem in het partnerschap te verwelkomen.”
— Dušan Stojanović, Managing Partner, True Global Ventures

“TGV heeft iets zeldzaams opgebouwd – een echt wereldwijd fonds met het netwerk, de portefeuille en de overtuiging om categorie-definiërende oprichters te ondersteunen in de meest cruciale stadia van hun groei. Na tientallen jaren te hebben gebouwd aan de grens van fintech en blockchain, ben ik verheugd om me aan te sluiten bij een team dat mijn overtuiging deelt dat AI en blockchain de bepalende investeringsthema’s van ons tijdperk zijn. Ik kijk ernaar uit om mijn ervaring in te zetten ter ondersteuning van True Global Ventures en de volgende fase van het bedrijf.”
— Tal Elyashiv, General Partner, True Global Ventures, Managing Partner, SPiCE VC

“Tal beschikt over een uitzonderlijke combinatie van ervaring als doorgewinterde durfkapitalist, succesvol ondernemer, ondernemer en specialist in het herstructureren van bedrijven.” Hij heeft daar niet alleen geïnvesteerd , maar ook iets opgebouwd. “De diepgaande en brede expertise van Tal en zijn praktische aanpak zullen een aanwinst zijn voor TGV en de bedrijven in onze portefeuille naarmate deze verder groeien.”
— Beatrice Lion, General Partner, True Global Ventures

OVER TRUE GLOBAL VENTURES
True Global Ventures (TGV) is een wereldwijd durfkapitaalbedrijf dat in een vroeg stadium investeert in AI-first bedrijven na de inkomsten. De huidige portfolio van TGV omvat Prezent, Cynch, COVU, Obligo, Ledger, Animoca Brands, Jus Mundi, Coding Giants en vele andere. Bijna alle portefeuillebedrijven zijn in de VS of komen de VS binnen. Met aanwezigheid in San Francisco, New York, Parijs, Londen, Stockholm, Dubai, Singapore en Hong Kong ondersteunt TGV visionaire oprichters die de volgende generatie van transformatieve technologie-ondernemingen bouwen. www.trueglobalventures.com

Foto – https://mma.prnewswire.com/media/2989447/1.jpg

SHANGHAI, May 29, 2026 — Forbes has released its 2026 Midas List, the definitive ranking of the world’s top venture capital investors. Alex Zhou, Managing Partner at Qiming Venture Partners, debuts at No. 80, recognizing his track record as a leading China-based investor focused on technology and artificial intelligence.

Known as the “Oscars of venture capital,” the Midas List is the most prestigious benchmark in global venture capital. The 2026 list marks its 25th anniversary, with intensified competition across the industry. Surging valuations for frontier companies including SpaceX, OpenAI and Anthropic have brought 25 new entrants to this year’s ranking.

Alex Zhou joined Qiming Venture Partners in 2014 and was promoted to Managing Partner in May 2024. He brings over 20 years of combined operational, entrepreneurial and investment experience, with a long-term focus on frontier technologies. He is one of the most active investors backing transformative AI and robotics startups globally.

Alex Zhou has delivered strong exit momentum in 2026. In the first five months of the year, four of his portfolio companies — Biren Technology, Zhipu AI, Axera Semiconductor and Viewtrix Technology — have completed public listings.

Alex Zhou adopts a pragmatic “half-step ahead” investment approach for tech and AI. Within his core areas of expertise, he identifies early industry inflection points and builds positions ahead of mainstream trends, avoiding speculative market hype. This forward-looking strategy has enabled him to capture outsized returns amid major technological paradigm shifts.

In late 2019, when China’s domestic GPU ecosystem remained immature and AI computing power was yet to gain widespread market recognition, Alex Zhou invested in Biren Technology at its founding. He led the company’s seed round and continued to support subsequent financings, helping the firm grow into the first Hong Kong-listed GPU company.

Alex Zhou made another early, high-impact bet on foundational AI in early 2022. At the time, large language models were still an emerging technology, and few investors recognized their commercial potential. His investment in Zhipu AI supported the development of the company’s first-generation GLM model, laying the foundation for its core technology development.

Alex Zhou’s early-stage focus also extends to embodied intelligence. He backed UBTECH Robotics eleven years ago and, in the current wave of embodied AI development, has led investments in a new batch of full-stack robotics companies integrating models and hardware, including TARS, Dexmal, GalaxyBot and ACE Robotics.

Founded in 2006, Qiming Venture Partners manages 11 USD funds and seven RMB funds, with $9.5 billion in assets under management. The firm focuses on two core pillars — technology and healthcare — forming a stable dual-driven investment strategy.

Qiming Venture Partners has maintained a long-term AI investment layout for over a decade. Starting with deep learning-focused investments in 2013, the firm has deployed more than RMB 12 billion into over 100 AI projects across the full industrial value chain, establishing itself as one of the most active and influential AI investors in China and Asia. The firm’s investment roadmap follows technological evolution across LLMs, multimodal AI and embodied intelligence, rather than short-term market trends.

In healthcare, Qiming Venture Partners is one of China’s earliest institutional investors dedicated to the sector. Over the past two decades, its healthcare team has invested in nearly 200 companies covering innovative pharmaceuticals, innovative medical devices, AI healthcare applications and other related areas. Its continuous investment has driven innovation in China’s life sciences industry and delivered practical clinical value globally.

Qiming Venture Partners’ technology and healthcare practices complement and empower one another. The firm’s healthcare industry expertise supports its judgments on AI+ healthcare applications opportunities, while its frontier tech insights help identify disruptive technology-driven healthcare startups. This cross-sector synergy forms Qiming Venture Partners’ key institutional advantage.

Qiming Venture Partners’ recurring recognition on the Midas List across technology, healthcare and AI reflects its long-built institutional capabilities: consistent focus on core sectors, proactive early deployment, and full-cycle investment expertise covering early to growth-stage companies.

Across both core verticals, Qiming Venture Partners executes systematic layout years before market consensus emerges, partnering with founders for long-term growth and achieving steady exit results. 

“For the next two decades, AI will stand as the most certain investment opportunity in China’s venture landscape,” said Duane Kuang, Founding Managing Partner of Qiming Venture Partners. The firm’s healthy cycle of fundraising, investment, portfolio management and exits continues to validate this long-term judgment.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine,  AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

Strong Project Economics and Growth Outlook With a Secure U.S. Bromine Supply

SPRING, Texas, May 28, 2026 — TETRA Technologies, Inc. (“TETRA” or the “Company”) (NYSE: TTI) today announced that its Board of Directors has conditionally approved the final investment decision (“FID”) for the development of the Company’s bromine production facility near Stamps, Arkansas (the “Evergreen Project”). The Board’s authorization is subject to the Company finalizing financing for the Evergreen Project. The decision marks a key milestone in TETRA’s transformation into a vertically integrated bromine producer and advances the Company’s ONE TETRA 2030 strategic plan.

“The Board’s approval of the final investment decision for our Arkansas bromine facility marks a major milestone in TETRA’s forty-five-year history,” said Brady Murphy, President and Chief Executive Officer. “This investment will secure a long-term, low-cost domestic supply of elemental bromine – the critical feedstock for our deepwater completion fluids and TETRA energy storage electrolyte products. By becoming vertically integrated, we would achieve bromine costs consistent with a fully integrated solution and provide long-term U.S.-based supply security in a highly concentrated market. The Evergreen Project positions us to meet accelerating demand for these products through 2030 and beyond.” 

Strategic Rationale

The global bromine market is estimated at approximately $2.3 billion in 2026 and is projected to grow at a compound annual growth rate of 5.5% through 2033 ⁽¹⁾, driven primarily by electrification trends, rising demand for deepwater, high-density completion fluids, and growing energy storage solutions. Currently, over 50% of global bromine supply originates in the Middle East ⁽²⁾, where ongoing geopolitical concerns have heightened focus on supply security.

TETRA owns mineral rights to approximately 40,000 acres of brine leases in Southwest Arkansas, which contain significant bromine resources, including 744 ktons of proven and probable bromine reserves in the Evergreen Unit and measured and indicated bromine resources of 3.57 million tons across all TETRA acreage.  TETRA has decided to use brine supplied by its Evergreen Unit as feed brine for the bromine production facility start-up, placing the project timeline entirely within TETRA’s control and maximizing the significant capital and operating expenditure synergies planned for future lithium and magnesium facilities and production.

Initial bromine production volumes for the Evergreen Project’s bromine facility are expected to be 25% above the Company’s long-term third-party supply agreement. Over time, the Company plans to double initial production rates to reach the bromine facility’s nameplate capacity. This investment would allow TETRA to minimize third-party purchases of elemental bromine, reducing the Company’s reliance on external suppliers and providing greater supply chain certainty.

Project Details

Key highlights of the Evergreen Project include the following:

• Net Present Value (“NPV”) The vertically integrated production case is expected to generate a bromine business NPV of $607 million, using a 10% discount rate, inclusive of approximately $220 million in remaining capital expenditures. Required capital expenditures will be funded over the next two years from a combination of cash from operations, credit facility borrowings and other financing sources.  The estimated NPV of our bromine business has been calculated using management’s estimates, which update the economics contained in the Company’s Definitive Feasibility Study dated September 22, 2025, and include updated inputs for anticipated costs and timeline of construction as well as future expectations regarding bromine demand and sales prices.  These estimates reflect management’s good faith estimate of potential return based on currently available information but are subject to change over time.  See “Forward Looking Statements” further in this press release.
• Timeline: The facility is expected to commence first production in early 2028, consistent with the Company’s ONE TETRA 2030 strategic targets.
• Supply Security: Secures TETRA’s bromine demand, which is forecast to increase by over 50% by 2030, and reduces the need for higher-cost third-party bromine purchases.
• Future Optionality: The Evergreen Unit infrastructure provides significant synergies for potential future development of lithium and magnesium resources from the same brine, further supporting TETRA’s critical minerals strategy.

Construction Progress

Phase 1 of the Evergreen Project, which included site preparation, power infrastructure, and installation of the bromine tower, was completed in December 2025. Phase 2, which encompasses the major infrastructure and equipment supporting the plant, is currently underway with mechanical completion targeted by the end of 2026. The entire facility is expected to be operational by the end of 2027, with first production anticipated in early 2028.

⁽¹⁾ Grandview Market Research

⁽²⁾ ICL Group LTD Company Overview Presentation March 2026 

Investor Contact

For further information, please contact Matt Sanderson, CFO, TETRA Technologies, Inc. at (281) 367-1983 or via email at [email protected] or Kurt Hallead, Treasurer and Vice President of Investor Relations at (281) 367-1983 or via email at [email protected].

Company Overview

TETRA Technologies, Inc. is an energy services and solutions company focused on developing environmentally conscious services and solutions that help make people’s lives better. With operations on six continents, the Company’s portfolio consists of Energy Services, Industrial Chemicals, and Critical Minerals. In addition to providing products and services to the oil and gas industry and calcium chloride for diverse applications, TETRA is expanding into the low-carbon energy market with chemistry expertise, key mineral acreage, and global infrastructure, helping to meet the demand for sustainable energy in the twenty-first century. Visit the Company’s website at www.onetetra.com for more information or connect with us on LinkedIn.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are identifiable by the use of the following words, the negative of such words, and other similar words: ‘anticipates’, ‘assumes’, ‘estimates’, ‘expects’, ‘intends’, ‘plans’, ‘projects’, ‘targets’, ‘will’, and ‘would.” These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timeline for the Evergreen Project, design capacity, production volumes, costs, financing sources, NPV projections, and strategic benefits of the Evergreen Project; statements regarding the global bromine market; statements regarding the Company’s ability to replace its current third-party supply agreements; and statements regarding the Company’s ONE TETRA 2030 strategic plan.

With respect to the Company’s disclosures of measured and indicated mineral resources, it is uncertain if all such resources will ever be economically developed. Investors are cautioned that mineral resources do not have demonstrated economic value and further exploration may not result in the estimation of a mineral reserve. Further, there are a number of uncertainties related to processing lithium, which is an inherently difficult process. Therefore, you are cautioned not to assume that all or any part of our resources can be economically or legally commercialized. 

These forward-looking statements are based on information available at the time of this release and are subject to a number of risks, uncertainties, and assumptions. For a discussion of these risks, uncertainties, and assumptions, the Company refers you to its filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company does not undertake any obligation to update or revise forward-looking statements.

SOURCE TETRA Technologies, Inc.

The latest financing follows Corgi’s previously announced $160 million raise on May 6 and continued expansion across AI-Driven commercial insurance infrastructure.

SAN FRANCISCO, May 28, 2026 — Today, Corgi announced a $106 million Series B1 round, led by TCV with participation from Prime Capital, Zone 2 Ventures, Oliver Jung, Leblon Capital, Kindred Ventures, Quadri Ventures, First Order Fund, Vocal Ventures, Nordstar, GSBackers, Repeat Ventures, 8188 Capital, and other strategic investors. This fresh round of funding brings the company’s valuation to $2.6 billion. The financing will support continued expansion of Corgi’s full-stack insurance platform and launch into new lines of commercial insurance.

This follows only three weeks after Corgi’s Series B announcement on May 6, in which the company disclosed $160 million in funding at a $1.3 billion valuation. Combined with the company’s previously announced $108 million Series A, this brings Corgi’s total funding amount to $378 million to accelerate the modernization of commercial insurance infrastructure. The company’s revenue has grown at a pace rarely seen in fintech or insurance.

“Commercial insurance infrastructure has historically been slow, manual, and difficult for operators to navigate,” said Nico Laqua, founder and CEO of Corgi. 

Laqua says the company was profitable last month, and that this new round would allow Corgi to expand quicker into new verticals such as trucking, small business, sports, and more. At this time, Corgi is on track to become one of the fastest growing companies by revenue.

From the start, Corgi has built for modern companies that have been underserved by legacy insurance: startups, founder-led businesses, and operators who expect speed and transparency from every vendor they work with. That focus has shaped the product, the distribution model, and the community Corgi continues to invest in as it scales.

About Corgi

Corgi is a full-stack insurance platform focused on rebuilding insurance and financial infrastructure. The company provides full-stack underwriting, claims handling, and embedded insurance solutions designed to make commercial coverage faster, more flexible, and operationally efficient.

Media Contact:

Erika Lee

[email protected]

SOURCE Corgi

CHICAGO, May 28, 2026 — As Nurses Month comes to a close, Nurse Capital, a venture capital firm dedicated to investing in nurse-led enterprises, is pleased to announce a new collaboration with the University City Science Center in Philadelphia to identify nurse-founded startups as candidates for the Science Center’s Capital Readiness Program (CRP).

The CRP is a five-day, in-person due diligence bootcamp for healthcare startups specializing in devices, diagnostics, and digital health. This highly selective, no-cost program prepares founders for their first significant round of venture capital funding ($1M+).

“Many nurse founders are bootstrapping, securing grant funding, raising small angel investments, piloting products, and winning pitch competitions to fund their startups,” said Beth A. Brooks, PhD, RN, FACHE, Co-founder and General Partner of Nurse Capital. “Yet for many of these founders, there exists a significant gap between early innovation and readiness for institutional venture capital.”

Nurse founders often bring deep clinical expertise and firsthand understanding of healthcare delivery, Brooks noted. Many also possess meaningful operational leadership experience inside complex healthcare systems. Their challenges, she pointed out, are gaining access to the commercialization strategy, investor readiness, fundraising structure, scaling support, and go-to-market infrastructure needed to transition from promising healthcare innovation into a venture-scalable business.

Nurse Capital’s collaboration with the University Science Center is designed to identify potential candidates for its Capital Readiness Program. The program is offered three times a year with 10 startups in each cohort. Participants receive one-on-one mentoring with Science Center Investors-in-Residence and other subject matter experts on the essentials of fundraising, from building a cap table to IP protections to board management. Participants also learn from case studies and “stress-test” scenarios that simulate real-world startup challenges; and gain a “360° perspective” on industry expectations from payors and providers.

“We strongly believe that healthcare innovation — and especially nurse-led healthcare innovation — benefits from more specialized founder-development infrastructure than what is often available through generalized startup incubators and accelerators,” said Nurse Capital General Partner Dan Weberg, PhD, MHI, RN, FAAN. “This collaboration with the Science Center is another step forward in our efforts to build a stronger network of support around nurse-specific innovation and entrepreneurship.”

The next CRP cohort session will take place December 7-11, 2026. The application deadline is August 21. Click here to learn more about the Capital Readiness Program and to apply.

About Nurse Capital
Nurse Capital is a venture capital fund based in Chicago that makes early-stage investments in nurse-led, high-growth-potential businesses that are transforming the future of healthcare. Learn more at https://nursecapital.net/.

About the University City Science Center
The Science Center is a premier catalyst of entrepreneurial activity, healthcare innovation, and economic growth. Recognized by The Brookings Institution as a top-tier investor, mentor, and economic development partner, the Science Center has supported hundreds of early- and growth-stage companies, driving a combined $7.8B in annual economic impact in Greater Philadelphia alone. Today, the organization works across the globe to accelerate the translation of health innovations into real-world solutions, while delivering nationally recognized STEM education to Philadelphia youth. For more information, visitsciencecenter.org.

SOURCE Nurse Capital

Appointment Strengthens U.S. Presence with TGV’s Deepening Focus in the Bay Area

SAN FRANCISCO and SINGAPORE, May 28, 2026 — True Global Ventures (TGV), global venture capital firm investing in visionary founders building category-defining AI-first technology companies, today announced the appointment of Tal Elyashiv as General Partner.

A seasoned entrepreneur, venture capitalist and technology executive with a distinguished career spanning Silicon Valley, Wall Street and Tel Aviv, Elyashiv brings a rare combination of deep-tech investing expertise, experience as an operator and institutional finance leadership to the firm. He will be relocating to the U.S. later this year, further reinforcing TGV’s growing presence in the San Francisco Bay Area.

An American Israeli with roots across two of the world’s foremost innovation ecosystems, Elyashiv has spent decades at the intersection of technology, financial services and venture capital.

Elyashiv is co-founder and Managing Partner of SPiCE VC, the first fully tokenized venture capital fund globally. SPiCE VC is also recognized as a top performing VC fund, with strong distributions vs paid in capital (DPI) and total value vs paid in capital (TVPI), significantly outperforming industry benchmarks. Elyashiv will continue his leadership at SPiCE VC (currently in its late harvesting stage) in parallel to his contribution at TGV.  The funds’ mandates are substantially different and there is no conflict of interest between the two roles.

In addition to his pioneering leadership at SPiCE VC, Elyashiv is also a co-founder of Securitize, now the leading platform for the tokenisation of real-world assets globally and a defining company in the digital securities space. He is also the author of two best-selling books, Blockchain Prophecies and the recently published Investing in Revolutions: Creating Wealth from Transformational Technology Waves, establishing him as one of the foremost thought leaders on the convergence of AI, blockchain, and quantum computing.

His prior roles in institutional finance include serving as a senior executive at Capital One, and Bank of America, COO at BondDesk Group, where he led the major turnaround of technology and service delivery, and as CTO and Head of New Businesses at 888.

Elyashiv’s appointment comes as TGV continues to accelerate its focus on AI-first business applications through TGV Fund 6, which leads investments at the late seed and Series A stages with a strong emphasis on California-based startups.

“Tal brings the fund management experience from a well-preforming VC that we seek at TGV — on top of that someone who has built companies, led institutions, and invested with conviction across multiple technology cycles. His American and Israeli roots give him a truly global lens, and his return to the U.S. aligns perfectly with TGV’s deepening focus on the Bay Area. We are thrilled to welcome him to the partnership.”
— Dušan Stojanović, Managing Partner, True Global Ventures

“TGV has built something rare — a genuinely global fund with the network, the portfolio, and the conviction to back category-defining founders at the most critical stages of their growth. After decades building at the frontier of fintech and blockchain, I am excited to join a team that shares my belief that AI and blockchain are the defining investment themes of our era. I look forward to bringing my experience bear in support of True Global Ventures and its next chapter.”
— Tal Elyashiv, General Partner, True Global Ventures, Managing Partner, SPiCE VC

“Tal’s combination as a seasoned venture investor, a successful operator, enterprise leadership and turnaround experience is exceptional. He has not only invested at the frontier — he has built there. Tal’s depth and breadth of expertise and hands-on execution will be an asset to TGV and our portfolio companies as they scale.”
— Beatrice Lion, General Partner, True Global Ventures

ABOUT TRUE GLOBAL VENTURES
True Global Ventures (TGV) is a global venture capital firm investing in post-revenues AI-first companies at the early stage. TGV’s current portfolio includes Prezent, Cynch, COVU, Obligo, Ledger, Animoca Brands, Jus Mundi, Coding Giants and many others. Almost all portfolio companies are in the U.S. or entering the U.S. With presence in San Francisco, New York, Paris, London, Stockholm, Dubai, Singapore and Hong Kong, TGV backs visionary founders building the next generation of transformative technology ventures. www.trueglobalventures.com

SOURCE True Global Ventures